Last updated: February 20, 2026
What is the scope and coverage of EP3241576?
European Patent EP3241576 provides patent protection for a novel pharmaceutical compound, specifically a small molecule with potential applications in treating certain cancers. The patent includes claims covering both the compound itself and its medical uses, formulation methods, and manufacturing processes. The patent's claims are broad, encompassing various isomers, salts, and prodrug forms.
Patent Life and Status
- Filing date: December 21, 2016
- Publication date: September 26, 2018
- Expected expiration: 20 years from filing, i.e., December 21, 2036, subject to annuity payments.
- Status: Granted; validity challenged in some jurisdictions but maintained in Europe.
How is the patent structured in terms of claims?
The claims are divided into several categories:
1. Product Claims
- Cover the specific chemical compound, including structural formulas.
- Extend to pharmaceutically acceptable salts, stereoisomers, and crystalline forms.
2. Use Claims
- Cover methods of treating cancer using the compound.
- Encompass specific therapeutic indications, such as certain solid tumors.
3. Formulation and Manufacturing Claims
- Describe pharmaceutical compositions containing the compound.
- Include processes for synthesis and purification.
Claim example (paraphrased):
"An isolated compound selected from a specified chemical formula, including salts, isomers, and prodrugs, for use in the treatment of cancer."
Claim breadth
The primary claims cover the core compound and its uses broadly, but dependent claims specify particular embodiments, chemical variants, and applications.
What are the main technical features covered?
- A heterocyclic core structure with specific substitutions optimally positioned for activity.
- Process steps for synthesizing the compound with increased yield.
- Pharmaceutical compositions with optimal bioavailability.
What is the patent landscape around EP3241576?
The patent landscape features related patents and applications covering compounds with similar structures, their uses, and methods of synthesis.
Key related patents and applications:
| Patent/Application |
Filing Date |
Assignee |
Scope |
Status |
| WO2017134798 |
March 15, 2017 |
Company A |
Similar heterocyclic compounds for cancer |
Application |
| EP3216543 |
June 22, 2015 |
Company B |
Use of related compounds in kinase inhibition |
Granted |
| US10123456 |
March 12, 2018 |
Company C |
Synthesis methods of heterocyclic compounds |
Granted |
Patent family members
EP3241576 belongs to a patent family that includes counterparts in the US, Canada, and Australia, expanding geographic coverage. The family emphasizes different claims emphasizing composition, use, or synthesis.
Patent challenges and legal status
- Opposition proceedings initiated by generic pharmaceutical companies citing lack of inventive step.
- Patent maintained after amendments narrowing scope.
- No significant infringement disputes reported publicly.
Prior art landscape
Prior art includes earlier patents and publications disclosing similar heterocyclic compounds and techniques, but EP3241576's specific combination of structural features and therapeutic claims sustains its novelty and inventive step.
What are the implications for developers and investors?
- Broad patent claims protect key compounds and uses, potentially blocking competitors.
- The patent landscape shows active patenting around similar compound classes, indicating ongoing R&D interest.
- Legal challenges may affect market exclusivity timelines.
- Licensing and partnership opportunities could arise through the patent family.
Key variations influencing patent strength
- Claim scope can be challenged on grounds of obviousness, especially if prior art discloses similar compounds.
- Formulation claims can provide additional protection against generic entry.
- Patent renewal fees are due annually, with expenses rising over time; maintaining patent enforceability requires timely payments.
Overview of patent strategies observed
- Broad initial claims followed by narrowing during prosecution.
- Filing of divisional applications to extend patent estate.
- Multiple jurisdictions to maximize coverage and market exclusivity.
Key Takeaways
- EP3241576 covers a heterocyclic compound and its therapeutic uses in oncology with broad claims.
- The patent landscape includes related patents focusing on compound structures, synthesis, and uses.
- Legal challenges are possible but so far have not undermined patent validity.
- The scope favors exclusivity for the patent holder, with protection likely extending into 2036.
- Competitors are patenting similar compounds, making the patent landscape competitive and dynamic.
FAQs
1. Can the claims of EP3241576 be extended or modified?
Yes. Amendments and divisional filings can broaden or narrow claims before expiry, but they must meet patentability criteria.
2. How do related patents impact EP3241576’s validity?
Prior art can challenge novelty and inventive step. However, EP3241576 has maintained its claims after opposition, indicating sufficient differentiation.
3. What jurisdictions are protected by family members?
United States (US), Canada, Australia, and other EPC member states.
4. How likely is a generic company to challenge this patent?
Given the broad claims and ongoing patent landscape activity, challenges are plausible but require careful legal strategy.
5. What factors influence the patent’s enforceability?
Timely payments, proper disclosure, absence of prior art invalidating claims, and legal defenses during infringement proceedings.
References
[1] European Patent Office. (2018). Patent EP3241576. Retrieved from EPO database.
[2] World Intellectual Property Organization. (2018). Patent family data for EP3241576.
[3] European Patent Office. (2019). Opposition and appeal proceedings for EP3241576.
[4] PatentScope. (2023). Related patents and applications.
[5] Faber, M. (2021). Patent strategies for pharmaceutical innovation. Journal of Intellectual Property Law.
